Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions
US7553488B2 · kind B2 · utility
4Cited by
4References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2003 |
| Grant date | Jun 30, 2009 |
| Priority date | — |
| Expiry date | Jun 20, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by using an anti-S100 polynucleotide or polypeptide inhibitor or antagonist, which is essentially targeted against S100A8, S100A9 or S100A12, alone or in combination with other inhibitors of chemokines or immune modulating products.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.